Chronic lymphocytic leukaemia: Up-dated recommendations on diagnosis and treatment

被引：8

作者：

Hallek, M

Bergmann, M

Emmerich, B

机构：

[1] Univ Cologne, Innere Med Klin 1, D-50924 Cologne, Germany

[2] Univ Munich, Klinikum Grosshadern, Med Klin 3, D-80539 Munich, Germany

[3] Univ Munich, Klinikum Innenstadt, Med Klin, D-80539 Munich, Germany

来源：

ONKOLOGIE | 2004年 / 27卷 / 01期

关键词：

chronic lymphatic leukaemia; treatment; diagnosis CLL; fludarabine; monoclonal antibodies; clinical trials;

D O I：

10.1159/000075613

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Diagnosis and treatment of chronic lymphatic leukaemia (CLL) are currently undergoing great change. New knowledge of prognosis factors and the numerous new therapeutic procedures now available, such as purine analogues, high-dose treatment and monoclonal antibodies are making major contributions to this progress. As a consequence, the options for treatment of CLL are considerably more diverse now than a few years ago, and now include procedures that take into account age and risk. At the same time, it should be emphasized that many important questions regarding the treatment of CLL remain unresolved. It is anticipated that these questions will be answered over the coming few years by including patients in multicentre studies like those being carried out by the German CLL study group.

引用

页码：97 / 104

页数：8

共 64 条

[21]

Gribben John G., 1999, Seminars in Hematology, V36, P18

[22]

Grillo-López AJ, 1999, SEMIN ONCOL, V26, P66

[23] Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia, (CLL):: results of a phase II study of the German CLL Study Group [J].

Hallek, M ;

Schmitt, B ;

Wilhelm, M ;

Busch, R ;

Kröber, A ;

Fostitsch, HP ;

Sezer, O ;

Herold, M ;

Knauf, W ;

Wendtner, CM ;

Kuse, R ;

Freund, M ;

Franke, A ;

Schriever, F ;

Nerl, C ;

Döhner, H ;

Thiel, E ;

Hiddemann, W ;

Brittinger, G ;

Emmerich, B .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) :342-348

[24]

Hallek M, 1997, LEUKEMIA, V11, pS4

[25]

HALLEK M, 2002, DTSCH ARZTEBL, V99, pA1294

[26] The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 [J].

Harris, NL ;

Jaffe, ES ;

Diebold, J ;

Flandrin, G ;

Muller-Hermelink, HK ;

Vardiman, J ;

Lister, TA ;

Bloomfield, CD .

MODERN PATHOLOGY, 2000, 13 (02) :193-207

[27] Rituximab therapy of patients with B-cell chronic lymphocytic leukemia [J].

Huhn, D ;

von Schilling, C ;

Wilhelm, M ;

Ho, AD ;

Hallek, M ;

Kuse, R ;

Knauf, W ;

Riedel, U ;

Hinke, A ;

Srock, S ;

Serke, S ;

Peschel, C ;

Emmerich, B .

BLOOD, 2001, 98 (05) :1326-1331

[28]

Juliusson G, 1997, HEMATOL CELL THER, V39, pS41, DOI 10.1007/s00282-997-0041-4

[29] Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia [J].

Juliusson, G ;

Christiansen, I ;

Hansen, MM ;

Johnson, S ;

Kimby, E ;

ElmhornRosenborg, A ;

Liliemark, J .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) :2160-2166

[30] Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy [J].

Keating, MJ ;

O'Brien, S ;

Lerner, S ;

Koller, C ;

Beran, M ;

Robertson, LE ;

Freireich, EJ ;

Estey, E ;

Kantarjian, H .

BLOOD, 1998, 92 (04) :1165-1171

← 1 2 3 4 5 6 7 →